ClinicalTrials.gg
RecruitingNCT05867849CBD-BDUpdated Apr 23, 2025

Cannabidiol for Bipolar Depression (CBD-BD)

A Phase 3 interventional study of Cannabidiol and Placebo in Bipolar Disorder, sponsored by University of British Columbia. Recruiting at 6 sites in Canada. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-23.

Sponsored by University of British Columbia · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Bipolar Disorder by University of British Columbia — 3 open to participants now, 3 under way, 1 of them phase 3. Bipolar Disorder · University of British Columbia.

Planned enrollment
2nd of 13
360 · median 44
Started
2023
the only one that year
Phase 3
5 of 15
1 open now
Registered
13th of 15
by date

Among the 15 studies in Bipolar Disorder by University of British Columbia, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 3, and was the 13th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

3 of the 15 studies in Bipolar Disorder by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Bipolar Disorder by University of British Columbia, or all of them as a file.
02

Study summary

Bipolar disorder (BD) is a lifelong condition characterized by recurrent episodes of depression and (hypo)mania. Periods of chronic and recurring depressive episodes are more common and can be severely disabling. Effective treatments exist; however, a significant portion of bipolar depressed patients do not respond to or have difficulty tolerating many of these interventions and thus look beyond established treatments to achieve symptom relief.

Cannabidiol (CBD), a chemical from the Cannabis sativa plant, has shown to have some beneficial effects on mood symptoms in a few small studies which assessed its effects in other mental and physical health conditions, but no large studies have been conducted to assess its safety and efficacy in bipolar depression. Additionally, several clinical studies have shown CBD to be safe and tolerable.

The primary objective of this study is to assess the effectiveness, safety and tolerability of cannabidiol in patients with bipolar depression (BD I or BD II) who have not responded to adequate trials with at least one first-line treatment for bipolar depression in comparison to those who will be treated with placebo. Placebo is an inactive substance that looks identical to the study medication but contains no therapeutic ingredient. This study is a randomized (like the flip of a coin), double-blind (you and the study team will not know which treatment arm you receive) study in which participants will receive either CBD or placebo added to their current treatment. Participants will have 5 clinical appointments and a phone appointment over a period of 10 weeks.

Read the detailed description

This is a Phase 3, 6-week, double-blind, parallel group randomized controlled trial to assess the efficacy, safety and tolerability of adjunctive CBD vs placebo in patients with acute bipolar depression (BD I or BD II) who have not responded to adequate trials with at least one first-line treatment for bipolar I disorder (i.e. lithium, lamotrigine, lurasidone, or quetiapine either as monotherapy or adjunctive therapy), or at least one first or second-line treatment for bipolar II depression (i.e. quetiapine, lithium, lamotrigine, sertraline, or venlafaxine as monotherapy or adjunctive therapy, or bupropion adjunctive therapy). After the baseline visit, patients who meet the eligibility criteria will enter a 6-week double-blind treatment phase during which participants will be randomized to adjunctive CBD or identical placebo.

Participants will be assessed at the screening visit, baseline visit, weeks 2, 4, and 6, or endpoint visit. All participants will receive a follow-up telephone call 2 weeks after the 6-week study endpoint or early termination visit to assess well-being.

All participants will continue treatment with their mood stabilizer and/or atypical antipsychotic as prescribed by their treating physicians.

03

Conditions studied

  • Bipolar Disorder

Keywords

  • Cannabidiol
  • Bipolar Disorder
  • Bipolar Depression
  • Mood Disorder
  • CBD
  • Depression
04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged 19 to 70 years (inclusive).
  2. diagnosis of BD I or BD II, AND a current major depressive episode confirmed by MINI 7.0.2 .
  3. All patients must be taking either a mood stabilizer (i.e. lithium or valproate; lamotrigine monotherapy as a mood stabilizer is acceptable for BD II patients only and not for BD I) OR an atypical antipsychotic OR a combination of these (two mood stabilizers or a mood stabilizer plus an atypical antipsychotic), at therapeutic doses. Medications and therapeutic doses are: lithium, serum level 0.6-1.2 mEq/L; divalproex/sodium valproate, serum level 350-700 uM/L(45-125 mcg/ml); risperidone 2-6 mg/day; olanzapine 5-30 mg/day; quetiapine IR or XR 300-900 mg/day; aripiprazole 10-30 mg/day; cariprazine 1.5-6 mg/day; and ziprasidone 80-160 mg/day. Combinations of these medications as outlined above, or the combination of any of them with lamotrigine 100-400 mg daily, or the combination of a mood stabilizer plus asenapine 5-20 mg/day are also permitted.
  4. Have received a minimum of 6-weeks treatment at adequate doses for treatment of current depressive episode with at least one CANMAT recommended treatment for bipolar I disorder (i.e. lithium, lamotrigine, lurasidone, or quetiapine either as monotherapy or adjunctive therapy), or at least one first or second-line treatment for bipolar II depression (i.e. quetiapine, lithium, lamotrigine, sertraline, or venlafaxine as monotherapy or adjunctive therapy, or bupropion adjunctive therapy).
  5. A MADRS score of ≥ 20 and a YMRS score of ≤ 12 (these cut off scores are standard in bipolar depression RCTs).
  6. Inpatient or outpatient status.
  7. All participants are required to agree to practice highly effective methods of (i.e. hormonal contraceptives, intrauterine device or system, vasectomy and tubal ligation, or double barrier methods of contraception) OR agree to completely abstain from heterosexual intercourse. Females who do not have are required to be for at least 1 year before the screening visit (confirmed by an FSH test) OR surgically sterile.
  8. The capability of understanding, consenting to and complying with study requirements.
  9. All concomitant medication must be at a stable dose for two weeks prior to the randomization visit.

Exclusion criteria

Exclusion Criteria:

  1. Current depressive episode greater than 12 months.
  2. A history of rapid cycling, defined as ≥ 4 mood episodes in the preceding 12 months.
  3. Current unstable or inadequately treated medical illness with the exception of current depression.
  4. Recently started taking a CANMAT-recommended treatment for the management of acute bipolar depressive episode, but has not had a trial for a minimum of 6 weeks with adequate doses.
  5. Recently (i.e. within the past 8 weeks) began structured psychotherapy (i.e. cognitive-behavioral therapy, interpersonal psychotherapy, family-focused therapy, or interpersonal and social rhythm therapy).
  6. Recently (i.e. within the past 8 weeks) started taking a stimulant medication. Concomitant treatment with stimulant medication is acceptable provided that the dose has been stable for a minimum of 8 weeks and is taken as prescribed by a physician.
  7. Current use of clozapine, tricyclic antidepressants, monoamine oxidase inhibitors, and first-generation antipsychotics.
  8. A history of non-response or intolerance to CBD.
  9. Current or past month daily use of CBD, or any product or drug that contains CBD. Occasional users will be included if they agree to refrain from using during the trial.
  10. A history of non-response to electroconvulsive therapy for the current depressive episode.
  11. A current diagnosis of other primary psychiatric disorders as assessed by a study investigator to be primary and causing greater impairment than BD.
  12. A lifetime history of a primary psychotic disorder (e.g. schizoaffective disorder, bipolar subtype) according to criteria.
  13. Patients who have met the DSM-5 criteria for a substance use disorder (except for nicotine or caffeine) within the past 6 months.
  14. Significant active suicidal ideation (as evidenced by MADRS suicide item ≥ 4).
  15. Pregnancy or lactation.
  16. Liver function tests ( and ALT) three times the .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Cannabidiol

    Cannabidiol 200 - 600 mg / day added to current treatment for 6 weeks.

    Drug: Cannabidiol

  • Placebo comparator
    Placebo

    Placebo added to current treatment for 6 weeks.

    Other: Placebo

Interventions

  • Cannabinoid

    Also known as: CBD

  • OtherPlacebo

    Inactive substance

06

What researchers measure

Primary outcomes

  1. Improvement in depressive symptoms in bipolar patients treated with Cannabidiol vs Placebo adjunctive therapy

    The Montgomery Asberg Depression Rating Scale (MADRS) will be used to measure change in depressive symptoms from baseline to endpoint. Scores range from 0 to 60, and lower scores reflect better clinical outcomes.

    Time frame: 6 weeks

Secondary outcomes

  1. Response rates

    Response rates are defined as patients showing ≥50% reduction in MADRS scores.

    Time frame: 6 weeks

  2. Remission rates

    Remission rates are defined as MADRS ≤ 10 and YMRS ≤ 8 at endpoint.

    Time frame: 6 weeks

  3. Treatment-emergent manic/hypomanic events

    The Young Mania Rating Scale (YMRS) will be used to determine the presence of any treatment-emergent manic or hypomanic events from baseline to endpoint. Scores range from 0 to 60, and lower scores reflect better clinical outcomes.

    Time frame: 6 weeks

  4. Objective depressive symptoms

    The 21-item Hamilton Depression Rating Scale (HAM-D 21) will be used to measure change in objective depressive symptoms from baseline to endpoint. Scores range from 0 to 62, and lower scores reflect better clinical outcomes.

    Time frame: 6 weeks

  5. Subjective depressive symptoms

    The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) and the Dimensional Anhedonia Rating Scale (DARS) will be used to measure change in subjective depressive symptoms from baseline to endpoint. Lower scores on the QIDS-SR reflect better clinical outcomes; higher scores on the DARS reflect better clinical outcomes.

    Time frame: 6 weeks

  6. Objective anxiety symptoms

    The Hamilton Anxiety Rating Scale (HAM-A) will be used to measure change in objective anxiety symptoms from baseline to endpoint. Scores range from 0 to 56 and lower scores reflect better clinical outcomes.

    Time frame: 6 weeks

  7. Subjective anxiety symptoms assessed by STAI

    The State-Trait Anxiety Inventory (STAI) will be used to measure change in subjective anxiety symptoms. Lower scores on the STAI reflect better clinical outcomes.

    Time frame: 6 weeks

  8. Subjective anxiety symptoms assessed by GAD-7

    The Generalized Anxiety Disorder 7-item (GAD-7) will be used to measure change in subjective anxiety symptoms. Lower scores on the GAD-7 reflect better clinical outcomes.

    Time frame: 6 weeks

  9. Overall psychiatric status

    The Clinical Global Impression - severity \& change scales will be used to measure change in global severity and global improvement in symptoms from baseline to endpoint. Scores range from 3 to 42, and higher scores reflect worsening in overall psychiatric status.

    Time frame: 6 weeks

  10. Psychotic symptoms

    The Positive and Negative Syndrome Scale (PANSS) will be used to measure change in psychotic symptoms from baseline to endpoint. Scores range from 7 to 49, and lower scores reflect better clinical outcomes.

    Time frame: 6 weeks

  11. Subjective cognitive functioning

    The Cognitive Complaints in Bipolar Disorder Risk Assessment (COBRA) and the Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function scale will be used to measure change in subjective cognitive functioning from baseline to endpoint. COBRA scores range from 0 to 48, and lower scores reflect better outcomes; PROMIS cognitive function scale scores range from 8 to 40, and higher scores reflect better outcomes.

    Time frame: 6 weeks

  12. Objective cognitive functioning

    The Screen for Cognitive Impairment in Psychiatry (SCIP) will be used to measure change in objective cognitive functioning from baseline to endpoint. Higher scores reflect better outcomes.

    Time frame: Week 6

  13. Sleep quality

    The Pittsburgh Sleep Quality Index (PSQI) will be used to measure changes in sleep quality and disturbance from baseline to endpoint. Lower scores reflect better sleep quality.

    Time frame: 6 weeks

  14. Suicidal thoughts and behaviours

    The Columbia-Suicide Severity Rating Scale (C-SSRS) will be used to measure change in suicidal thoughts and behaviours from baseline to endpoint. Scores range from 0 to 37, and lower scores reflect better clinical outcomes.

    Time frame: 6 weeks

  15. Quality of Life assessed by QoL.BD

    The Brief Quality of Life in Bipolar Disorder (QoL.BD) will be used to measure change in quality of life from baseline to endpoint. Higher scores reflect higher quality of life.

    Time frame: 6 weeks

  16. Daily functioning

    The Functioning Assessment Short Test (FAST) will be used to measure change in daily functioning from baseline to endpoint. Lower scores reflect better daily functioning.

    Time frame: 6 weeks

  17. Health services utilization

    A healthcare utilization diary will be used to measure improvement in health services utilization from baseline to endpoint.

    Time frame: 6 weeks

  18. Adverse events

    Adverse events will be measured objectively using an open-ended form and subjectively using the Frequency, Intensity, and Burden of Side Effects Rating (FIBSER). FIBSER scores range from 0 to 18, and lower scores reflect better outcomes.

    Time frame: 6 weeks

07

Study locations

3 of 6 sites recruiting
  • UBC Mood Disorders Centre
    Vancouver, British Columbia V6T 1Z3, Canada
    Recruiting
  • St. Joseph's Healthcare
    Hamilton, Ontario L8N 3K7, Canada
    Recruiting
    • Gomes Fabiano, MD · Principal investigator
  • Providence Care Hospital
    Kingston, Ontario K7L 4X3, Canada
    Recruiting
    • Roumen Milev, MD · Principal investigator
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
    Not yet recruiting
    • Ayal Schaffer, MD · Principal investigator
  • Centre for Addiction and Mental Health (CAMH)
    Toronto, Ontario M6J1H4, Canada
    Not yet recruiting
    • Arun Ravindran, MD · Principal investigator
    • Nisha Ravindran, MD · Sub investigator
  • Douglas Mental Health University Institute
    Montreal, Quebec H4H 1R3, Canada
    Not yet recruiting
    • Serge Beaulieu, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2029, 74 months after the start.

Of 43 phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2023
First posted
May 22, 2023
StartActual
Oct 15, 2023
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2030
Last update
Apr 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05867849
Responsible party
Lakshmi N Yatham (Investigator, University of British Columbia) — Principal investigator
First posted
May 22, 2023
Start date
Oct 15, 2023
Primary completion
Dec 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Apr 23, 2025

Study contacts

Nazlin Walji, BSc
Contact
nazlin.walji@ubc.ca
604-822-7294
Shannon Reid, BA
Contact
shannon.reid@ubc.ca
604-822-8045
Lakshmi N Yatham, MBBS, MRCPsy
principal investigator · University of British Columbia, Department of Psychiatry

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion